SURF - Surface Oncology's immunotherapy product candidates show promising data in tumor activity

Surface Oncology (SURF) will present preclinical findings supporting its lead product programs, SRF388 (targeting IL-27) and SRF617 (targeting CD39) at the American Association for Cancer Research ((AACR)) 2021 Annual Meeting.Presentation summaries are as follows: SRF617 is a potent inhibitor of CD39 enzymatic activity both in vitro and in vivo.CD39 inhibition predominantly shaped the transcriptional landscape of myeloid cells and dendritic cells, and generally induced proinflammatory conditions ad thereby support future clinical studies of SRF617 for treating patients with cancer. IL-27 signaling suppresses natural killer ((NK)) cells within the tumor microenvironment, promoting hepatocellular carcinoma ((HCC)) development in vivo.Inhibiting IL-27 signaling leads to tumor growth inhibition and suppressed HCC development in a non-alcoholic steatohepatitis-driven HCC model with concomitant enhancement of NK cell activity.These findings indicate that IL-27 blockade regulates NK cell-mediated control of HCC and is a promising therapeutic target in liver cancer.#AACR21

For further details see:

Surface Oncology's immunotherapy product candidates show promising data in tumor activity